Covid-19 roundup: BeiGene snags rights to po­ten­tial an­ti­body treat­ment; Beef­ing up man­u­fac­tur­ing ops, Re­gen­eron adds 400 jobs at Irish fa­cil­i­ty

BeiGene snagged ex­clu­sive rights to de­vel­op and com­mer­cial­ize Sin­glomics Bio­phar­ma­ceu­ti­cals’ Covid-19 an­ti­bod­ies out­side of Greater Chi­na, thus ex­pand­ing the com­pa­ny’s search for a po­ten­tial treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.